



Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies

Ray Lorenzoni, MD

Tiffany Berthod, MSN, RN, CPN, CCRC

Andrea Orsey, MD, MSCE

Ilana Waynik, MD

Olga H Toro-Salazar, MD, EMBA


What is a Clinical Pathway?

An evidence-based guideline that decreases unnecessary variation and helps promote safe, effective, and consistent patient care.



Objectives of Pathway

- To develop a comprehensive interdisciplinary pediatric pathway to standardize primary and secondary prevention of a change in systolic performance, also referred to as **cancer therapy-related cardiac dysfunction (CTRCD)**
- To utilize multimodality imaging to assess for change in systolic performance as indicated
- To prevent heart failure and the progression of heart failure
- To ensure appropriate and timely referrals to necessary specialists and ancillary service providers



Why is Pathway Necessary?

- Among the nearly 500,000 long-term childhood cancer survivors in the United States, more than half were treated with cardiotoxic cancer therapy, which results in a 15-fold increased rate of heart failure and an 8-fold increased rate of premature cardiac death.
- No comprehensive pediatric cardio-oncology pathway has been published to guide prevention and management of cardiac effects of cancer treatment.
 - Cardio-oncology is an emerging field
 - Childhood cancer survivors receive numerous cancer treatments that are cardio-toxic
 - We want to preserve heart function throughout cancer therapy so they can get the cancer treatments they need
 - Want to limit dose modifications
 - Want to limit held doses
 - Prevent or limit the long term cardiovascular effects of cancer treatments



- **Appendix A** lists the common effects of cardiotoxic cancer agents
- Targeted Molecular Therapies are growing in the pediatric population & will continue to be used. These also have cardiotoxic effects.

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity
Primary and Secondary Prevention Strategies
Appendix A: List of Cardiotoxic Agents and Effects

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Cardiac effect	LVD/HF	Myocarditis	Arterial Thrombosis	Atherosclerosis, Coronary Spasm	Pericardial disease	Valve Disease	HTN	Pulmonary HTN or fibrosis
Conventional Therapies								
Anthracyclines								
Platinum-based Cisplatin								
Alkylating Agents Cyclophosphamide, Ifosfamide								
Vinca Alkaloids[^] Vinblastine, Vincristine								
Antimetabolites 5-fluorouracil (5-FU), Capecitabine, Cytarabine								
Microtubule Inhibitors (primarily used in adults) Paclitaxel, Docetaxel								
Targeted Molecular Therapies*								
VEGF Inhibitors Sunitinib, Pazopanib, Bevacizumab								
BRAF Inhibitors Dabrafenib								
MEK Inhibitors Trametinib, Mirdametinib								
mTOR Inhibitors Everolimus								
BCR-ABL TK Inhibitors Imatinib								
BCR-ABL1 Inhibitors Dasatinib								
Proteasome Inhibitors Bortezomib, Carfilzomib								
Immunotherapies								
Immune checkpoint inhibitors								
CAR-T-cell therapy								
Radiation								
Steroids								
Imaging								
Echo (preferred screening modality)								
CMR								
CT								

[^] Vinca Alkaloids only cardiotoxic when used in combination with anthracyclines

* There is continuous introduction of additional target molecular therapies such as BRAF/MEK inhibitors that induce cardiotoxicity. Refer to literature and cancer protocol for additional details.

Herrmann, J. (2020). Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. *Nat Rev Cardiol*, 17(8), 474-502.
<https://doi.org/10.1038/s41569-020-0348-1>



RETURN TO
THE BEGINNING



CONTACTS: OLGA H TORO SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRC
 ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
 LAST UPDATED: 07.17.25


©2019 Connecticut Children's Medical Center. All rights reserved.

Background: Heart Failure

Since outcomes of clinical heart failure (HF) are generally poor, it is vitally important to have a systematic way to both prevent and also provide early intervention.

Heart Failure Symptoms

NYHA Class	Symptoms
Class I	No symptoms and can perform ordinary physical activity without limitations
Class II	Mild symptoms and slight limitation of physical activity; No symptoms at rest
Class III	Marked limitation of physical activity (even with less than ordinary activity) due to symptoms; Comfortable at rest
Class IV	Unable to carry out any physical activity; Severe limitations; Symptoms present even at rest



Outcomes after a diagnosis of clinical HF are generally poor, with 5-year overall survival <50%.


Armenian SH et al. Cardiology research and practice. 2012;2012:713294.

Background: Heart Failure

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity
Primary and Secondary Prevention Strategies
Appendix G: Stages of Heart Failure

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Appendix G: Stages of Heart Failure




Cardio-oncology prevention begins upon cancer diagnosis **not** after cancer treatment has finished. Primary and secondary prevention of heart failure (HF) can include the following:

1. Use of Dexrazoxane
2. Monitoring heart function via echos/CMRs
3. Promoting heart healthy diet
4. Promoting physical activity
5. Utilizing cardiac medication(s) to preserve/improve heart function → prevent/reduce the need to dose reduce or skip cancer treatments

Background: Heart Failure

Appendix G: Stages of Heart Failure




- Heart failure stage A & B are **at risk for heart failure**. All oncology patients that receive cardiotoxic therapy are considered heart failure stage A.
- Heart failure stage A** means the patient is at high risk for heart failure due to the cardiotoxic cancer therapy, **but do not** have any structural heart disease (as shown via echo or CMR) or symptoms (heart failure symptoms reviewed after heart failure stages reviewed)

Background: Heart Failure

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity
Primary and Secondary Prevention Strategies
Appendix G: Stages of Heart Failure

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Appendix G: Stages of Heart Failure




Heart failure stage B means the patient is at high risk for heart failure due to the cardiotoxic cancer therapy **and has** structural heart disease (as shown via echo or CMR), but does not have any symptoms. This is the stage where we want to intervene so they do not escalate to stage C or D

Background: Heart Failure

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity
Primary and Secondary Prevention Strategies
Appendix G: Stages of Heart Failure

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Appendix G: Stages of Heart Failure



- Heart failure stage C & D patients have **clinical heart failure**
- Heart failure stage C patients have **structural heart disease** and **are experiencing symptoms**
- Heart failure stage D patients have **refractory heart failure**, **are experiencing symptoms**, and require advance heart failure therapy (i.e. implantable mechanical heart pump, IV medication, etc.) and/or heart transplant


- Children's Oncology Group (COG) define adequate cardiac function for clinical trial enrollment as:
 - Shortening fraction of $\geq 28\%$ by echocardiogram
 - Ejection fraction of $\geq 50\%$ by radionuclide angiogram
- However, our pathway takes a more conservative approach to help prevent progression of heart failure:
 - A change in systolic performance, also known as **CTRCD**, is defined as:
 - EF $< 55\%$
 - A decrease in EF of 10 percentage points or more
 - GLS $< -17\%$ (more negative is good, less negative is bad)
 - Z-score < -2.0 for EF (located in the table within an echo report)

This is the Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Clinical Pathway.

We will be reviewing each component in the following slides.

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Primary Prevention Strategies

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



The cardio-oncology labs can be ordered by using an order set

All order sets will be reviewed later in this presentation

As per current practice within the hematology/oncology psychosocial team

As per current practice within the hematology/oncology department. PI: Dr. Lau

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Primary Prevention Strategies


THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Inclusion Criteria: Any pediatric cancer patient who receives cardiotoxic therapy ([Appendix A: List of Cardiotoxic Agents and Effects](#))

Exclusion criteria: Pediatric cancer patients not receiving cardiotoxic therapy

Assessment for ALL Patients:

- Baseline echocardiogram per COG protocol
- Baseline cardiac MRI if indicated¹
- Baseline labs (ordered by Cardiology): High sensitivity troponin T (hsTnT), N-terminal pro-BNP, vitamin D, lipid panel (includes triglycerides), fructosamine, HbA1C, ferritin (*do NOT obtain NT-proBNP and ferritin at initial cancer diagnosis*)
- Assess physical fitness and consult PT as needed.
- Nutrition evaluation as needed
- Psychosocial assessment as provided by Hematology Oncology department (Social Determinants of Health via PAT 3.1 General Version, [PROMIS Pediatric-37 Profile v2.0](#) and [PROMIS Parent Proxy-37 Profile v2.0](#), etc.)
- Patient will be offered enrollment to the existing biorepository of biologic sample(s) for future biomarker and genetic research



NEXT PAGE

- **Risk stratification** is currently completed by the cardio-oncology department.

The cardio-oncology Epic registry is under development and is designed to auto calculate risk score.

- The Therapeutic profile tab will now have a cardio-oncology section (also referred to as event)

Therapeutic Profile

← Ped Cardiology Springboard Report Hem/Onc Snapshot **Therapeutic Profile** Facesheet SDOH Active Orders Labs Visit Orders

Cardio-Oncology

Baseline Risk Scoring: Low risk
Baseline Heart Failure Stage: ACC/AHA Stage A heart failure (at risk for cardiomyopathy)
Baseline Cardiac Function (via ECHO and/or CMR): Normal Echo (see report for more details)

The cardio-oncology section will be used:

1. Baseline


- Risk scoring
- Heart failure stage
- Baseline cardiac function (via Echo and/or CMR)

2. Any major cardio-onc (i.e. +CTRCD)

- Updated risk scoring
- Updated heart failure stage
- Updated cardiac function (via Echo and/or CMR)
- Cardiac medications

NICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Tertiary and Secondary Prevention Strategies

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT.



Appendix B: Risk Stratification Tool

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix B: Risk Stratification Tool

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



Risk Stratification Tool for Patients Receiving Cancer Treatment

Step 1: Score your patient's cardiovascular and cancer related risk categories

Step 2: Total the cardiovascular and cancer related risk categories

Step 3: Determine if patient is at low, moderate, or high risk for developing cardiac toxicity

Cardiovascular Related Risk Categories	
Body Mass Index (BMI) kg/m²: BMI information within the last year <i>Use percentiles for patients 0-20 years of age</i>	
☐ <85 th percentile or BMI <25	0
☐ 85 th -<95 th percentile or BMI 25 – 29.9	0.5
☐ ≥95 th percentile or BMI 30 – 34.9	1
☐ ≥120% of 95 th % percentile OR BMI ≥35, whichever is lower based on age and sex	1.5
Lipid Panel: Performed within 3 years	
☐ Normal (LDL-c <110 mg/dL AND triglycerides <150 mg/dL)	0
☐ Low-Moderate Risk (LDL-c 110-129 mg/dL OR triglycerides 150-199 mg/dL)	0.5
☐ High Risk (LDL-c ≥130 mg/dL OR triglycerides ≥200 mg/dL)	1
Pre-Diabetes/Diabetes: Performed within 1 year	
☐ Normal glucose/A1c (HbA1c: <5.7%, 2-hr OGTT: <140 mg/dL, or Fasting: <100 mg/dL)	0
☐ Prediabetes (HbA1c: 5.7-6.4%, 2hr OGTT: 140-199 mg/dL, or Fasting: 100-125 mg/dL)	0.5
☐ Diabetes (HbA1c: ≥6.5%, 2-hr OGTT: ≥200 mg/dL, or Fasting: ≥126 mg/dL)	1
Ferritin: Lab result at any point in time	
☐ ≤1,000 µg/L	0
☐ >1,000 µg/L	1
Cardiorespiratory Fitness (CRF): Performed within the last 2 years	
☐ Good-Superior CRF based on relative VO ₂ max for age & sex (≥ 80% of predicted value or ≥ 8 METs)	0
☐ Fair-Very Poor CRF based on relative VO ₂ max for age & sex (60 - < 80% of predicted or 5-7 METs)	1
☐ Less than Very Poor CRF is categorized as functional disability based on relative VO ₂ max for age & sex (<60% of predicted or <5 METs)	2
Previous Heart Disease at Diagnosis	
☐ No	0
☐ Yes	2
Hypertension (HTN): per AHA (≥ 13 years old) & AAP guidelines (<13 years old)	
☐ Normal	0
☐ Elevated/Pre-HTN	0.5
☐ Stage 1	1
☐ Stage 2	3
Change in Systolic Performance*: During or after cancer therapy completion	
☐ No	0
☐ Yes	1.5

Cancer Related Risk Categories	
Age at Cancer Diagnosis	
☐ ≥5 years	0
☐ 1-4 years	1
☐ <1 year	2
Sex: Assigned at birth	
☐ Male	0
☐ Female	1
Radiation: to heart region only	
☐ None	0
☐ <5 Gy	0.5
☐ 5-15 Gy	1
☐ >15-30 Gy	3
☐ >30 Gy	5
Vinca alkaloids[^]	
☐ No	0
☐ Yes	0.5
Alkylating Agents (i.e. CPM, IFOS)	
☐ No	0
☐ Yes	1.5
Anthracycline (AC) Cumulative Dose	
☐ <101 mg/m ²	0
☐ 101-200 mg/m ²	0.5
☐ >200-250 mg/m ²	1
☐ >250-300 mg/m ²	2
☐ >300 mg/m ²	3
Dexrazoxane Given: applicable only if patient received ≥ 200mg/m ² of AC	
☐ No	2
☐ Yes	0
Transplant: Please total scores for ALL transplants patient has undergone (if patient has a tandem transplants patient score would be 2)	
☐ No	0
☐ Autologous	1
☐ Allogenic	2

[^] Only when given in combination with AC

*Change in Systolic Performance definition:

1. Left Ventricular Ejection Fraction (LVEF) less than normal for age AND/OR
2. Global Longitudinal Strain (GLS) less than normal for age AND/OR
3. Z score less than -2 OR
4. A decrease in EF of more than 10 percentage points from baseline

Risk probability for developing cardiac toxicity		
Low Risk	Moderate Risk	High Risk
0 - <6	6 - <11	≥11
Patient is automatically High Risk if they have a <u>change in systolic performance</u> *		

Created by: Olga H.Toro-Salazar MD, Tiffany Berthod MSN, RN, CPN, CCRG, Andrea Orsey MD, MSCE, Eileen Gillan MD, Shailendra Upadhyay MD, Karen Rubin MD



RETURN TO
THE BEGINNING



CONTACTS: OLGA H TORO SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRG
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
LAST UPDATED: 07.17.26



Appendix B: Risk Stratification Tool

- This refers to gender at birth, as in children, females have a higher cardio-oncology risk

- Vinca alkaloids only gets 0.5 points if Anthracyclines were also administered as part of the patient's cancer treatment plan. Vincristine on it's own would score "0." Of note, vinca alkaloids and anthracyclines do not need to be administered within the same cycle.

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix B: Risk Stratification Tool

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Risk Stratification Tool for Patients Receiving Cancer Treatment
Step 1: Score your patient's cardiovascular and cancer related risk categories

Patients Receiving Cancer Treatment
Cardiovascular and cancer related risk categories
and cancer related risk categories
low, moderate, or high risk for developing cardiac toxicity

Cancer Related Risk Categories	
Age at Cancer Diagnosis	
☐ ≥5 years	0
☐ 1-4 years	1
☐ <1 year	2
Gender: at birth	
☐ Male	0
☐ Female	1
Radiation: to heart region only	
☐ None	0
☐ <5 Gy	0.5
☐ 5-14.9 Gy	1
☐ 15-29.9 Gy	3
☐ >30 Gy	5
Vinca alkaloids[^]	
☐ No	0
☐ Yes	0.5
Alkylating Agents (i.e. CPM, IFOS)	
☐ No	0
☐ Yes	1.5
Anthracycline (AC) Cumulative Dose	
☐ <101 mg/m ²	0
☐ 101-200 mg/m ²	0.5

Created by: Olga H.Toro-Salazar MD, Tiffany Berthod MSN, RN, CPN, CCRG, Andrea Orsey MD, MSCE, Eileen Gillan MD, Shailendra Upadhyay MD, Karen Rubin MD



RETURN TO
THE BEGINNING



CONTACTS: OLGA H TORO SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRG
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
LAST UPDATED: 07.17.25

Appendix B: Risk Stratification Tool

- Dexrazoxane (DRZ) is typically always given prior to anthracycline (AC) doses.
- However, previously DRZ wasn't standard process so there may be patients for whom you will have to check "No"

- Transplant scores are to be summed.
- Examples:
 - If a patient has had a Tandem transplant (2 autologous transplants) they would receive a 2.
 - If a patient had an autologous transplant and an allogenic transplant they would receive a 3.

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix B: Risk Stratification Tool

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



Risk Stratification Tool for Patients Receiving Cancer Treatment

Step 1: Score your patient's cardiovascular and cancer related risk categories
Step 2: Total the cardiovascular and cancer related risk categories
Step 3: Determine if patient is at low, moderate, or high risk for developing cardiac toxicity

Cardiovascular Related Risk Categories		Cancer Related Risk Categories	
Body Mass Index (BMI) kg/m²: BMI information within the last year <i>Use percentiles for patients 0-20 years of age</i>		Age at Cancer Diagnosis	
☐ <85 th percentile or BMI <25	0	☐ ≥5 years	0
☐ 85 th -<95 th percentile or BMI 25 – 29.9	0.5	☐ 1-4 years	1
☐ ≥95 th percentile or BMI 30 – 34.9	1	☐ <1 year	2
☐ ≥120% of 95 th % percentile OR BMI ≥35, whichever is lower based on age and sex	1.5	Sex: Assigned at birth	
		☐ Male	0
		☐ Female	1
Lipid Panel			
☐ >300 mg/m ²	3		
Dexrazoxane Given: applicable only if patient received ≥ 200mg/m ² of AC			
☐ No	2		
☐ Yes	0		
Transplant: Please total scores for ALL transplants patient has undergone (if patient has 2 Tandem transplants patient score would be 2)			
☐ No	0		
☐ Autologous/Tandem	1		
☐ Allogenic	2		

*Change

- Left Ventricular Ejection Fraction (LVEF) less than normal for age AND/OR
- Global Longitudinal Strain (GLS) less than normal for age AND/OR
- Z score less than -2 OR
- A decrease in EF of more than 10 percentage points from baseline

Risk probability for developing cardiac toxicity		
Low Risk	Moderate Risk	High Risk
0 - <6	6 - <11	≥11
Patient is automatically High Risk if they have a change in systolic performance*		

Created by: Olga H.Toro-Salazar MD, Tiffany Berthod MSN, RN, CPN, CCRG, Andrea Orsey MD, MSCE, Eileen Gillan MD, Shailendra Upadhyay MD, Karen Rubin MD



RETURN TO
THE BEGINNING



CONTACTS: OLGA H. TORO-SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRG
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
LAST UPDATED: 07.17.25

©2019 Connecticut Children's Medical Center. All rights reserved.



Appendix B: Risk Stratification Tool

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix B: Risk Stratification Tool

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



Risk Stratification Tool for Patients Receiving Cancer Treatment
Step 1: Score your patient's cardiovascular and cancer related risk categories
Step 2: Total the cardiovascular and cancer related risk categories
Step 3: Determine if patient is at low, moderate, or high risk for developing cardiac toxicity

Risk score	Look back time period	Comments
BMI	1 year	
Lipid Panel	3 years	
Pre-Diabetes Diabetes	1 year	Order in which to prioritize labs: HbA1c, 2-hr OGTT, fasting glucose
Ferritin	At any point in time	

Cardiovascular Related Risk Categories

Body Mass Index (BMI) kg/m²: BMI information within the last year
Use percentiles for patients 0-20 years of age

☐ <85th percentile or BMI <25

0

☐ 85th-<95th percentile or BMI 25 – 29.9

0.5

☐ ≥95th percentile or BMI 30 – 34.9

1

☐ ≥120% of 95th % percentile OR BMI ≥35, whichever is lower based on age and sex

1.5

Lipid Panel: Performed within 3 years

☐ Normal (LDL-c <110 mg/dL AND triglycerides <150 mg/dL)

0

☐ Low-Moderate Risk (LDL-c 110-129 mg/dL OR triglycerides 150-199 mg/dL)

0.5

☐ High Risk (LDL-c ≥130 mg/dL OR triglycerides ≥200 mg/dL)

1

Pre-Diabetes/Diabetes: Performed within 1 year

☐ Normal glucose/A1c (HbA1c: <5.7%, 2-hr OGTT: <140 mg/dL, or Fasting: <100 mg/dL)

0

☐ Prediabetes (HbA1c: 5.7-6.4%, 2hr OGTT: 140-199 mg/dL, or Fasting: 100-125 mg/dL)

0.5

☐ Diabetes (HbA1c: ≥6.5%, 2-hr OGTT: ≥200 mg/dL, or Fasting: ≥126 mg/dL)

1

Ferritin: Lab result at any point in time

☐ ≤1,000 µg/L

0

☐ >1,000 µg/L

1

Cancer Related Risk Categories

Age at Cancer Diagnosis

☐ ≥5 years

0

☐ 1-4 years

1

☐ <1 year

2

Sex: Assigned at birth

☐ Male

0

☐ Female

1

Radiation: to heart region only

☐ None

0

☐ <5 Gy

0.5

Body Mass Index (BMI) kg/m²: BMI information within the last year
Use percentiles for patients 0-20 years of age

☐ <85th percentile or BMI <25

0

☐ 85th-<95th percentile or BMI 25 – 29.9

0.5

☐ ≥95th percentile or BMI 30 – 34.9

1

☐ ≥120% of 95th % percentile OR BMI ≥35, whichever is lower based on age and sex

1.5

Lipid Panel: Performed within 3 years

☐ Normal (LDL-c <110 mg/dL AND triglycerides <150 mg/dL)

0

☐ Low-Moderate Risk (LDL-c 110-129 mg/dL OR triglycerides 150-199 mg/dL)

0.5

☐ High Risk (LDL-c ≥130 mg/dL OR triglycerides ≥200 mg/dL)

1

Pre-Diabetes/Diabetes: Performed within 1 year

☐ Normal glucose/A1c (HbA1c: <5.7%, 2-hr OGTT: <140 mg/dL, or Fasting: <100 mg/dL)

0

☐ Prediabetes (HbA1c: 5.7-6.4%, 2hr OGTT: 140-199 mg/dL, or Fasting: 100-125 mg/dL)

0.5

☐ Diabetes (HbA1c: ≥6.5%, 2-hr OGTT: ≥200 mg/dL, or Fasting: ≥126 mg/dL)

1

Ferritin: Lab result at any point in time

☐ ≤1,000 µg/L

0

☐ >1,000 µg/L

1

*Change in Systolic Performance definition:
1. Left Ventricular Ejection Fraction (LVEF) less than normal for age AND/OR
2. Global Longitudinal Strain (GLS) less than normal for age AND/OR
3. Z score less than -2 OR
4. A decrease in EF of more than 10 percentage points from baseline

Risk probability for developing cardiac toxicity		
Low Risk	Moderate Risk	High Risk
0 - <6	6 - <11	≥11
Patient is automatically High Risk if they have a change in systolic performance*		

Created by: Olga H.Toro-Salazar MD, Tiffany Berthod MSN, RN, CPN, CCRG, Andrea Orsey MD, MSCE, Eileen Gillan MD, Shailendra Upadhyay MD, Karen Rubin MD

RETURN TO THE BEGINNING

CONTACTS: OLGA H TORO SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRG
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
LAST UPDATED: 07.17.25



Appendix B: Risk Stratification Tool

- In pediatrics use the American Academy of Pediatrics (AAP) guidelines:
 - <https://www.mdcalc.com/calc/4052/aap-pediatric-hypertension-guidelines>
- For adult patients use the AHA guidelines

BLOOD PRESSURE CATEGORY	SYSTOLIC mm Hg (upper number)		DIASTOLIC mm Hg (lower number)
NORMAL	LESS THAN 120	and	LESS THAN 80
ELEVATED	120 – 129	and	LESS THAN 80
HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 1	130 – 139	or	80 – 89
HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 2	140 OR HIGHER	or	90 OR HIGHER
HYPERTENSIVE CRISIS (consult your doctor immediately)	HIGHER THAN 180	and/or	HIGHER THAN 120

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix B: Risk Stratification Tool

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



Risk Stratification Tool for Patients Receiving Cancer Treatment

- Step 1: Score your patient's cardiovascular and cancer related risk categories
Step 2: Total the cardiovascular and cancer related risk categories
Step 3: Determine if patient is at low, moderate, or high risk for developing cardiac toxicity

Cardiovascular Related Risk Categories	
Body Mass Index (BMI) kg/m²: BMI information within the last year <i>Use percentiles for patients 0-20 years of age</i>	
☐ <85 th percentile or BMI <25	0
☐ 85 th -<95 th percentile or BMI 25 – 29.9	0.5
☐ ≥95 th percentile or BMI 30 – 34.9	1
☐ ≥120% of 95 th % percentile OR BMI ≥35, whichever is lower based on age and sex	1.5
Lipid Panel: Performed within 3 years	
☐ Normal (LDL-c <110 mg/dL AND triglycerides <150 mg/dL)	0
☐ Low-Moderate Risk (LDL-c 110-129 mg/dL OR triglycerides 150-199 mg/dL)	0.5
☐ High Risk (LDL-c ≥130 mg/dL OR triglycerides ≥200 mg/dL)	1
Pre-Diabetes/Diabetes: Performed within 1 year	
☐ Normal glucose/A1c (HbA1c: <5.7%, 2-hr OGTT: <140 mg/dL, or Fasting: <100 mg/dL)	0
☐ Prediabetes (HbA1c: 5.7-6.4%, 2hr OGTT: 140-199 mg/dL, or Fasting: 100-125 mg/dL)	0.5
☐ Diabetes (HbA1c: ≥6.5%, 2-hr OGTT: ≥200 mg/dL, or Fasting: ≥126 mg/dL)	1
Ferritin: Lab result at any point in time	
☐ ≤1,000 µg/L	0
☐ >1,000 µg/L	1
Cardiorespiratory Fitness (CRF): Performed within the last 2 years	
☐ Good-Superior CRF based on relative VO ₂ max for age & sex (≥ 80% of predicted value or ≥ 8 METs)	0
☐ Fair-Very Poor CRF based on relative VO ₂ max for age & sex (60 - < 80% of predicted or 5-7 METs)	1
☐ Less than Very Poor CRF is categorized as functional disability based on relative VO ₂ max for age & sex (<60% of predicted or <5 METs)	2
Previous Heart Disease at Diagnosis	
☐ No	0
☐ Yes	1
Cancer Related Risk Categories	
Age at Cancer Diagnosis	
☐ ≥5 years	0
☐ 1-4 years	1
☐ <1 year	2
Sex: Assigned at birth	
☐ Male	0
☐ Female	1
Radiation: to heart region only	
☐ None	0
☐ <5 Gy	0.5
☐ 5-15 Gy	1
☐ >15-30 Gy	3
☐ >30 Gy	5
Vinca alkaloids^A	
☐ No	0
☐ Yes	0.5
Alkylating Agents (i.e. CPM, IFOS)	
☐ No	0
☐ Yes	1.5
Anthracycline (AC) Cumulative Dose	
☐ <101 mg/m ²	0
☐ 101-200 mg/m ²	0.5
☐ >200-250 mg/m ²	1
☐ >250-300 mg/m ²	2
☐ >300 mg/m ²	3
Dexrazoxane Given: applicable only if patient received ≥ 200mg/m ² of AC	
☐ No	0
☐ Yes	0.5

Hypertension (HTN): per AHA (≥ 13 years old) & AAP guidelines (<13 years old)

☐ Normal	0
☐ Elevated/Pre-HTN	0.5
☐ Stage 1	1
☐ Stage 2	3

*Change in Systolic Performance definition:

- Left Ventricular Ejection Fraction (LVEF) less than normal for age AND/OR
- Global Longitudinal Strain (GLS) less than normal for age AND/OR
- Z score less than -2 OR
- A decrease in EF of more than 10 percentage points from baseline

Risk probability for developing cardiac toxicity		
Low Risk	Moderate Risk	High Risk
0 - <6	6 - <11	≥11
Patient is automatically High Risk if they have a change in systolic performance*		

Created by: Olga H.Toro-Salazar MD, Tiffany Berthod MSN, RN, CPN, CCRG, Andrea Orsey MD, MSCE, Eileen Gillan MD, Shailendra Upadhyay MD, Karen Rubin MD



RETURN TO
THE BEGINNING




CONTACTS: OLGA H. TORO-SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRG
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
LAST UPDATED: 07.17.25

©2019 Connecticut Children's Medical Center. All rights reserved.



Clinical Tools available for HTN



Under Clinical References in Epic:

- 1) AAP HTN Guidelines
- 2) UpToDate

Utilizing UpToDate for pediatric BPs



A screenshot of a web browser showing the UpToDate search results for "pediatric hypertension". The browser's address bar displays the URL: https://www.uptodate.com/contents/search?search=pediatric%20hypertension&sp=0&searchType=PLAIN_TEXT&source=USER_INPUT&searchControl=TOP_PU. The UpToDate logo is on the left, and the search bar contains the text "pediatric hypertension". To the right of the search bar are links for "Help" and a user profile for "Tiffany Ruiz". Below the search bar is a navigation bar with tabs: "< Back", "All" (which is underlined), "Adult", "Pediatric", "Patient", and "Graphics". Below the navigation bar, it says "Showing results for **pediatric hypertension**". The first search result is titled "[Hypertension in children and adolescents: Evaluation](#)", which is highlighted with a red box. Below the title is a snippet of text: "...children with HTN will be reviewed here. The epidemiology, etiology, diagnosis, and treatment of **childhood HTN** are discussed separately. In addition, the evaluation for hypertensive emergency is presented ...". Below the snippet are several links: "Goals", "Definition", "Summary and recommendations", "2017 AAP updated definitions for pediatric BP", and "Primary and secondary pediatric HTN distinguishing features".

UpToDate® pediatric hypertension

Help ▼ Tiffany Ruiz ▼

< Back All Adult Pediatric Patient Graphics

Showing results for **pediatric hypertension**

[Hypertension in children and adolescents: Evaluation](#)

...children with HTN will be reviewed here. The epidemiology, etiology, diagnosis, and treatment of **childhood HTN** are discussed separately. In addition, the evaluation for hypertensive emergency is presented ...

Goals

Definition

Summary and recommendations

2017 AAP updated definitions for pediatric BP

Primary and secondary pediatric HTN distinguishing features

Utilizing UpToDate for pediatric BPs



UpToDate®

pediatric hypertens

< Back

Topic Graphics (11)

BP

- Normal BP males
- Normal BP females
- Primary and secondary pediatric HTN distinguishing features
- Causes of HTN in children
- Pediatric CVD risk factors

2 of 11

Export to Powerpoint

Print

Share

Bookmark

Rate ☆☆☆☆☆

Blood pressure levels for males by age and height percentile

BP (percentile)	Systolic BP (mmHg)							Diastolic BP (mmHg)						
	Height percentile or measured height							Height percentile or measured height						
	5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
1 year														
Height (in)	30.4	30.8	31.6	32.4	33.3	34.1	34.6	30.4	30.8	31.6	32.4	33.3	34.1	34.6
Height (cm)	77.2	78.3	80.2	82.4	84.6	86.7	87.9	77.2	78.3	80.2	82.4	84.6	86.7	87.9
50 th	85	85	86	86	87	88	88	40	40	40	41	41	42	42
90 th	98	99	99	100	100	101	101	52	52	53	53	54	54	54
95 th	102	102	103	103	104	105	105	54	54	55	55	56	57	57
95 th + 12 mmHg	114	114	115	115	116	117	117	66	66	67	67	68	69	69

Elevated HTN

Stage 1 HTN

Stage 2 HTN

Appendix B: Risk Stratification Tool

Pediatric Cardiorespiratory Fitness (<20 years old) is based off of peak VO_2 % predicted

- In Epic, Stress Test results are found under “Procedures”
- If you click **Maximum Voluntary Ventilation** once, you’ll see the Peak VO_2 located in the **Summary of Findings**

Cardiorespiratory Fitness (CRF): Performed within the last 2 years	
☐ Good-Superior CRF based on relative VO_2 max for age & sex ($\geq 80\%$ of predicted value or ≥ 8 METs)	0
☐ Fair-Very Poor CRF based on relative VO_2 max for age & sex (60 - < 80% of predicted or 5–7 METs)	1
☐ Less than Very Poor CRF is categorized as functional disability based on relative VO_2 max for age & sex (<60% of predicted or <5 METs)	2

Procedure
Maximum Voluntary Ventilation
Spirometry
Simple Cardio Stress

← ↻ 🏠 🖨 📄	📖 📱
during recovery.	
10. Symptoms: Patient reported fatigue at peak exertion	
11. Peak VO_2 = 22.0 mL/kg/min; 67% predicted.	
12. Evidence of obstructive/restrictive lung disease	
The results of this test are questionable due to patient's inability to perform the maneuvers as	


Reminder: The Cardio-oncology dept is responsible for risk scoring. This is for your knowledge.

Appendix B: Risk Stratification Tool

- Cardiopulmonary Stress Test yields a peak VO_2/VO_2 max value
- This indicates a patient's cardiorespiratory fitness and is the most important predictor of morbidity and mortality

Cardiac Monitoring:

- Echocardiograms and ECG per cancer treatment protocol ([Appendix C: Echocardiogram Algorithm](#))(See [page 4](#) if prolonged QTc)
- Cardiac MRI at time of diagnosis and maximal anthracycline therapy, otherwise follow ([Appendix D: MRI Algorithm](#))
- Cardiopulmonary Stress Test following EOT



Appendix B: Risk Stratification Tool

Reminder: Cardio-oncology is responsible for risk scoring. This is for your knowledge

Pediatric
Cardiorespiratory
Fitness (<20
years old) is
based off of peak
VO₂ % predicted

- Please use the “VO2 Max/Pred (%)” As seen highlighted in red in the PDF report

<u>Exercise</u>	<u>Rest</u>	<u>AT</u>	<u>VO2 Max</u>	<u>Pred</u>	<u>AT / Pred (%)</u>	<u>VO2 Max/Pred (%)</u>
Time (min)	9:40	15:53	16:29			
Ex Time (min)		6:09	6:45			
---- WORK ----						
Speed (MPH)		3.4	2.5			
Grade (%)		14.0				
---- VENTILATION ----						
Vt BTPS (L)	0.90	1.55	1.84			
RR (br/min)	14	48	46			
VE BTPS (L/min)	12.3	74.3	83.9	116.0	64	72
BR (%)	89.4	35.7	27.4			
SpO2 (%)	93	94	93			
---- O2 CONSUMPTION ----						
VO2 (mL/kg/min)	4.1	19.6	22.0	32.9	60	67
VO2 (L/min)	0.42	1.99	2.23	3.34	60	67
VCO2 (L/min)	0.35	2.24	2.76	4.04	56	68
----	----	----	----	----	----	----

Appendix B: Risk Stratification Tool

Reminder: Cardio-oncology is responsible for risk scoring. This is for your knowledge

SUMMARY OF FINDING

1. Exercise protocol: Bruce Protocol
2. This was a maximal stress test. Respiratory exchange ratio (RER) = 1.37.
3. Exercise time was 07 minutes and 08 seconds. Maximum work load was 9.2 METS.
4. Underlying rhythm was sinus rhythm.
5. Heart rate response was normal. Peak heart rate= 170 BPM; 86% of the maximum age predicted heart rate.

One way to see the MET information

<u>Exercise</u>	<u>Rest</u>	<u>AT</u>	<u>VO2 Max</u>	<u>Pred</u>	<u>AT / Pred (%)</u>	<u>VO2 Max/Pred (%)</u>
Time (min)	9:52	14:00	17:02			
Ex Time (min)		4:07	7:09			
---- WORK ----						
Speed (MPH)		2.5	1.7			
Grade (%)	10.0	12.0				
---- VENTILATION ----						
Vt BTPS (L)	0.57	1.36	1.57			
RR (br/min)	24	37	57			
VE BTPS (L/min)	13.9	49.8	89.2	130.0	38	69
BR (%)	89.3	61.7	31.4			
SpO2 (%)	100	100	100			
---- O2 CONSUMPTION ----						
VO2 (mL/kg/min)	4.5	20.8	23.8	31.3	67	76
VO2 (L/min)	0.38	1.76	2.01	2.64	66	76
VCO2 (L/min)	0.35	1.70	2.75	3.20	53	86
RER	0.93	0.97	1.37			
METS	1.3	6.0	6.8	9.2	67	76

Another way to see the MET information

Appendix B: Risk Stratification Tool

Adult VO₂ max (≥ 20 years) Male Table

TABLE 3.8 • Treadmill-Based Cardiorespiratory Fitness Classifications (VO₂max) by Age and Sex

VO ₂ max (mL O ₂ · kg ⁻¹ · min ⁻¹)		MEN					
		Age Group (yr)					
Percentile		20-29	30-39	40-49	50-59	60-69	
95	Superior	66.3	59.8	55.6	50.7	43.0	
90		61.8	56.5	52.1	45.6	40.3	
85	Excellent	59.3	54.2	49.3	43.2	38.2	
80		57.1	51.6	46.7	41.2	36.1	
75		55.2	49.2	45.0	39.7	34.5	
70	Good	53.7	48.0	43.9	38.2	32.9	
65		52.1	46.6	42.1	36.3	31.6	
60		50.2	45.2	40.3	35.1	30.5	
55		49.0	43.8	38.9	33.8	29.1	
50	Fair	48.0	42.4	37.8	32.6	28.2	
45		46.5	41.3	36.7	31.6	27.2	
40		44.9	39.6	35.7	30.7	26.6	
35		43.5	38.5	34.6	29.5	25.7	
30	Poor	41.9	37.4	33.3	28.4	24.6	
25		40.1	35.9	31.9	27.1	23.7	
20		38.1	34.1	30.5	26.1	22.4	
15		35.4	32.7	29.0	24.4	21.2	
10	Very poor	32.1	30.2	26.8	22.8	19.8	
5		29.0	27.2	24.2	20.9	17.4	

Use the VO₂ max obtained, locate their age, determine which category they fall under. Example: 35 year old male with a VO₂ max of 39% would fall under the **poor category** and **score a 1** on the risk score.

Reminder: Cardio-oncology is responsible for risk scoring. This is for your knowledge

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix B: Risk Stratification Tool

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



Risk Stratification Tool for Patients Receiving Cancer Treatment

Step 1: Score your patient's cardiovascular and cancer related risk categories
Step 2: Total the cardiovascular and cancer related risk categories
Step 3: Determine if patient is at low, moderate, or high risk for developing cardiac toxicity

Cardiovascular Related Risk Categories		Cancer Related Risk Categories	
Body Mass Index (BMI) kg/m ² : BMI information within the last year Use percentiles for patients 0-20 years of age		Age at Cancer Diagnosis	
☐ <85 th percentile or BMI <25	0	☐ ≥5 years	0
☐ 85 th -<95 th percentile or BMI 25 – 29.9	0.5	☐ 1-4 years	1
☐ ≥95 th percentile or BMI 30 – 34.9	1	☐ <1 year	2
☐ ≥120% of 95 th percentile OR BMI ≥35, whichever is lower based on age and sex	1.5	Sex: Assigned at birth	
Lipid Panel: Performed within 3 years		☐ Male	0
☐ Normal (LDL-c <110 mg/dL AND triglycerides <150 mg/dL)	0	☐ Female	1
☐ Low-Moderate Risk (LDL-c 110-129 mg/dL OR triglycerides 150-199 mg/dL)	0.5	Radiation: to heart region only	
☐ High Risk (LDL-c ≥130 mg/dL OR triglycerides ≥200 mg/dL)	1	☐ None	0
Pre-Diabetes/Diabetes: Performed within 1 year		☐ <5 Gy	0.5
☐ Normal glucose/A1c (HbA1c: <5.7%, 2-hr OGTT: <140 mg/dL, or Fasting: <100 mg/dL)	0	☐ 5-15 Gy	1
☐ Prediabetes (HbA1c: 5.7-6.4%, 2-hr OGTT: 140-199 mg/dL, or Fasting: 100-125 mg/dL)	0.5	☐ >15-30 Gy	3
		☐ >30 Gy	5
		Vincal alkaloids ^a	
		☐ No	0
Cardiorespiratory Fitness (CRF): Performed within the last 2 years		patient has undergone (if patient has a tandem transplant patient score would be 2)	
☐ Good-Superior CRF based on relative VO ₂ max for age & sex (≥ 80% of predicted value or ≥ 8 METs)	0	☐ No	0
☐ Fair-Very Poor CRF based on relative VO ₂ max for age & sex (60 - < 80% of predicted or 5-7 METs)	1	☐ Autologous	1
☐ Less than Very Poor CRF is categorized as functional disability based on relative VO ₂ max for age & sex (<60% of predicted or <5 METs)	2	☐ Allogenic	2
☐ Elevated/Pre-HTN	0.5	^a Only when given in combination with AC	
☐ Stage 1	1		
☐ Stage 2	3		
Change in Systolic Performance*: During or after cancer therapy completion			
☐ No	0		
☐ Yes	1.5		

*Change in Systolic Performance definition:

1. Left Ventricular Ejection Fraction (LVEF) less than normal for age AND/OR
2. Global Longitudinal Strain (GLS) less than normal for age AND/OR
3. Z score less than -2 OR
4. A decrease in EF of more than 10 percentage points from baseline

Risk probability for developing cardiac toxicity		
Low Risk	Moderate Risk	High Risk
0 - <6	6 - <11	≥11
Patient is automatically High Risk if they have a change in systolic performance*		

Created by: Olga H.Toro-Salazar MD, Tiffany Berthod MSN, RN, CPN, CCRP, Andrea Orsey MD, MSCE, Eileen Gillan MD, Shailendra Upadhyay MD, Karen Rubin MD



RETURN TO
THE BEGINNING



CONTACTS: OLGA H. TORO-SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRP
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
LAST UPDATED: 07.17.25

©2019 Connecticut Children's Medical Center. All rights reserved.



Appendix B: Risk Stratification Tool

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix B: Risk Stratification Tool

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Adult VO₂ max (≥ 20 years) Female Table

WOMEN						
Age Group (yr)						
Percentile		20-29	30-39	40-49	50-59	60-69
95	Superior	56.0	45.8	41.7	35.9	29.4
90	Excellent	51.3	41.4	38.4	32.0	27.0
85		48.3	39.3	36.0	30.2	25.6
80		46.5	37.5	34.0	28.6	24.6
75		44.7	36.1	32.4	27.6	23.8
70	Good	43.2	34.6	31.1	26.8	23.1
65		41.6	33.5	30.0	26.0	22.0
60		40.6	32.2	28.7	25.2	21.2
55		38.9	31.2	27.7	24.4	20.5
50	Fair	37.6	30.2	26.7	23.4	20.0
45		35.9	29.3	25.9	22.7	19.6
40		34.6	28.2	24.9	21.8	18.9
35		33.6	27.4	24.1	21.2	18.4
30	Poor	32.0	26.4	23.3	20.6	17.9
25		30.5	25.3	22.1	19.9	17.2
20		28.6	24.1	21.3	19.1	16.5
15		26.2	22.5	20.0	18.3	15.6
10	Very poor	23.9	20.9	18.8	17.3	14.6
5		21.7	19.0	17.0	16.0	13.4
		(n = 410)	(n = 608)	(n = 843)	(n = 805)	(n = 408)

Percentiles from cardiopulmonary exercise testing on a treadmill with measured maximal volume of oxygen consumed per unit time ($\dot{V}O_{2max}$) ($mL O_2 \cdot kg^{-1} \cdot min^{-1}$). Data obtained from the Fitness Registry and the Importance of Exercise National Database (FRIEND) Registry for men and women who were considered free from known cardiovascular disease.

Adapted with permission from (124).

Reminder: Cardio-oncology is responsible for risk scoring. This is for your knowledge



Risk Stratification Tool for Patients Receiving Cancer Treatment

Step 1: Score your patient's cardiovascular and cancer related risk categories
Step 2: Total the cardiovascular and cancer related risk categories
Step 3: Determine if patient is at low, moderate, or high risk for developing cardiac toxicity

Cardiovascular Related Risk Categories	
Body Mass Index (BMI) kg/m ² : BMI information within the last year	
Use percentiles for patients 0-20 years of age	
☐ <85 th percentile or BMI <25	0
☐ 85 th -<95 th percentile or BMI 25 – 29.9	0.5
☐ ≥95 th percentile or BMI 30 – 34.9	1
☐ ≥120% of 95 th percentile OR BMI ≥35, whichever is lower based on age and sex	1.5
Lipid Panel: Performed within 3 years	
☐ Normal (LDL-c <110 mg/dL AND triglycerides <150 mg/dL)	0
☐ Low-Moderate Risk (LDL-c 110-129 mg/dL OR triglycerides 150-199 mg/dL)	0.5
☐ High Risk (LDL-c ≥130 mg/dL OR triglycerides ≥200 mg/dL)	1
Pre-Diabetes/Diabetes: Performed within 1 year	
☐ Normal glucose/A1c (HbA1c: <5.7%, 2-hr OGTT: <140 mg/dL, or Fasting: <100 mg/dL)	0
☐ Prediabetes (HbA1c: 5.7-6.4%, 2hr OGTT: 140-199 mg/dL, or Fasting: 100-125 mg/dL)	0.5
Cancer Related Risk Categories	
Age at Cancer Diagnosis	
☐ ≥25 years	0
☐ 1-4 years	1
☐ <1 year	2
Sex: Assigned at birth	
☐ Male	0
☐ Female	1
Radiation: to heart region only	
☐ None	0
☐ <5 Gy	0.5
☐ 5-15 Gy	1
☐ >15-30 Gy	3
☐ >30 Gy	5
Vinca alkaloids ^a	
☐ No	0
Cardiorespiratory Fitness (CRF): Performed within the last 2 years	
☐ Good-Superior CRF based on relative VO ₂ max for age & sex (≥ 80% of predicted value or ≥ 8 METs)	0
☐ Fair-Very Poor CRF based on relative VO ₂ max for age & sex (60 - < 80% of predicted or 5-7 METs)	1
☐ Less than Very Poor CRF is categorized as functional disability based on relative VO ₂ max for age & sex (<60% of predicted or <5 METs)	2
☐ Elevated/Pre-HTN	0.5
☐ Stage 1	1
☐ Stage 2	3
Change in Systolic Performance*: During or after cancer therapy completion	
☐ No	0
☐ Yes	1.5
patient has undergone (if patient has a tandem transplants patient score would be 2)	
☐ No	0
☐ Autologous	1
☐ Allogenic	2

*Change in Systolic Performance definition:
1. Left Ventricular Ejection Fraction (LVEF) less than normal for age AND/OR
2. Global Longitudinal Strain (GLS) less than normal for age AND/OR
3. Z score less than -2 OR
4. A decrease in EF of more than 10 percentage points from baseline

Risk probability for developing cardiac toxicity		
Low Risk	Moderate Risk	High Risk
0 - <6	6 - <11	≥11
Patient is automatically High Risk if they have a change in systolic performance*		

Created by: Olga H.Toro-Salazar MD, Tiffany Berthod MSN, RN, CPN, CCRG, Andrea Orsey MD, MSCE, Eileen Gillan MD, Shailendra Upadhyay MD, Karen Rubin MD



RETURN TO THE BEGINNING



CONTACTS: OLGA H TORO-SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRG
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
LAST UPDATED: 07.17.25



Appendix B: Risk Stratification Tool

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix B: Risk Stratification Tool

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



Risk Stratification Tool for Patients Receiving Cancer Treatment

Step 1: Score your patient's cardiovascular and cancer related risk categories
Step 2: Total the cardiovascular and cancer related risk categories
Step 3: Determine if patient is at low, moderate, or high risk for developing cardiac toxicity

Cardiovascular Related Risk Categories		Cancer Related Risk Categories	
Body Mass Index (BMI) kg/m²: BMI information within the last year <i>Use percentiles for patients 0-20 years of age</i>		Age at Cancer Diagnosis	
☐ <85 th percentile or BMI <25	0	☐ ≥5 years	0
☐ 85 th -<95 th percentile or BMI 25 – 29.9	0.5	☐ 1-4 years	1
☐ ≥95 th percentile or BMI 30 – 34.9	1	☐ <1 year	2
☐ ≥120% of 95 th % percentile OR BMI ≥35, whichever is lower based on age and sex	1.5	Sex: Assigned at birth	
		☐ Male	0
		☐ Female	1
Lipid Panel: Performed within 3 years		Radiation: to heart region only	
☐ Normal (LDL <110 mg/dL AND triglycerides <150 mg/dL)	0	☐ No	0
		☐ Yes	1.5
Cardiorespiratory Fitness (CRF): Performed within the last 2 years		Anthracycline (AC) Cumulative Dose	
☐ Good-Superior CRF based on relative VO ₂ max for age & sex (≥ 80% of predicted value or ≥ 8 METs)	0	☐ <101 mg/m ²	0
☐ Fair-Very Poor CRF based on relative VO ₂ max for age & sex (60 – < 80% of predicted or 5–7 METs)	1	☐ 101-200 mg/m ²	0.5
☐ Less than Very Poor CRF is categorized as functional disability based on relative VO ₂ max for age & sex (<60% of predicted or <5 METs)	2	☐ >200-250 mg/m ²	1
		☐ >250-300 mg/m ²	2
		☐ >300 mg/m ²	3
Previous Heart Disease at Diagnosis		Doxorubicin Given: applicable only if patient received ≥ 200mg/m ² of AC	
☐ No	0	☐ No	2
☐ Yes	2	☐ Yes	0
Hypertension (HTN): per AHA (≥ 13 years old) & AAP guidelines (<13 years old)		Transplant: Please total scores for ALL transplants patient has undergone (if patient has a tandem transplants patient score would be 2)	
☐ Normal	0	☐ No	0
☐ Elevated/Pre-HTN	0.5	☐ Autologous	1
☐ Stage 1	1	☐ Allogenic	2
☐ Stage 2	3		
Change in Systolic Performance*: During or after cancer therapy completion			
☐ No	0		
☐ Yes	1.5		

*Change in Systolic Performance definition:

1. Left Ventricular Ejection Fraction (LVEF) less than normal for age AND/OR
2. Global Longitudinal Strain (GLS) less than normal for age AND/OR
3. Z score less than -2 OR
4. A decrease in EF of more than 10 percentage points from baseline

Risk probability for developing cardiac toxicity		
Low Risk	Moderate Risk	High Risk
0 - <6	6 - <11	≥11
Patient is automatically High Risk if they have a change in systolic performance*		

Created by: Olga H.Toro-Salazar MD, Tiffany Berthod MSN, RN, CPN, CCRG, Andrea Orsey MD, MSCE, Eileen Gillan MD, Shailendra Upadhyay MD, Karen Rubin MD



RETURN TO THE BEGINNING



The following constitute as previous heart disease at diagnosis:

- Baseline change in systolic performance (also known as myocardial dysfunction or CTRCD) *previously explained on slide 11*
- Pericardial effusion
- Pericardial tamponade
- Previous history of congenital and/or acquired heart disease
- Tumor with cardiac hemodynamic effects (i.e. tumor compression on the heart or blood vessels – reported at the top of echo reports)
- Myocarditis

CONTACTS: OLGA H. TORO-SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRG
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
LAST UPDATED: 07.17.25

©2019 Connecticut Children's Medical Center. All rights reserved.



View Heart Failure Risk Details on Problem List

Under the Problem List the team will place a **Cardiovascular and Mediastinum** diagnosis for cardio-oncology patients.

Problem List

14 items

Problems from outside sources need reconciliation.


Cardiovascular and Mediastinum

ACC/AHA stage B heart failure

An Epic user can click on the problem “ACC/AHA heart failure stage,” and details of this conditions can be seen. An example of this is seen on the next slide.

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Primary Prevention Strategies

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



View Heart Failure Risk Details on Problem List

Problem Detail

Noted: 1/29/2019

Overview Addendum 10/30/2023 11:22 AM by Tiffany L Ruiz, RN

Time stamp will show last time it was updated

Cardio-oncology history

1. **Cancer Diagnosis:** B-lymphoblastic lymphoma
2. **Age at Diagnosis:** 15 years
3. **Cancer Protocol:** AALL0932
4. **Anthracyclines received:** Please see life time dosing section below
5. **Radiation Therapy:** No
6. **Previous heart disease at diagnosis:** Congenital anomaly of heart
7. **Transplant:** No
8. **Other chemotherapies given:** Vincristine, Cyclophosphamide, Cytarabine, Methotrexate, Etoposide, 6MP, 6TG, steroids
9. **Risk factors for CTRCD:** Low risk
10. **Cardiovascular History:** None during cancer therapy.
11. **Heart failure medications:** None indicated

Lifetime Dose Tracking

- doxorubicin: 76.366 mg/m2 (126 mg) = 16.97 % of the maximum lifetime dose of 450 mg/m2
- cyclophosphamide: 1,050.955 mg/m2 (1,650 mg) = 14.01 % of the maximum lifetime dose of 7,500 mg/m2
- Total Anthracycline: 76.366 mg/m2 (126 mg) = 16.97 % of the maximum lifetime dose of 450 mg/m2

Previously conducted echos:

Date	EF% (3D)	GLS %	FS %	Med E' Peak cm/sec	Notes/Comments
	60		41.2	9.5	Mild aortic valve insufficiency
	63.4		41.9	9.5	Poor acoustic window. Buckling of the mitral valve leaflets to the plane of the annulus without prolapse. Trivial mitral valve insufficiency
	57		29	11.1	
	58	-	31		Limited acoustic windows, limited imaging.

Previously conducted cardiac MRI (CMR): None previously performed


Previously conducted stress tests (CPET): None previously performed

Risk Stratification Tool Use

Of note, risk scoring also takes place at other time periods during the patients cancer treatment, not just at diagnosis, max anthracycline therapy, and therapy completion

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Primary Prevention Strategies

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.




Page 1: Primary Prevention Other Tips on Management

- Please note that “Interventions for ALL Patients” serves as a guide for clinicians
- A box on the right lists the indications for obtaining a cardiac MRI (CMR)



Interventions for ALL Patients:

- Optimize physical activity by encouraging participation with exercise regimens including those prescribed or recommended by ([Reference: Pediatric Oncology Exercise Manual](#))
- Optimize heart healthy diet as per Nutrition evaluation
- Continue psychosocial support and intervention as provided by the Hematology Oncology psychosocial team
- If ferritin is $>1,000\mu\text{g/L}$ and not downward- trending, consider obtaining cardiac and hepatic T2* MRI
- Consultation with specialists to promote cardiac health (i.e. endocrinology) as needed
- Review cardio-oncology education ([Patient and Guardian Handouts](#))




Prolonged QTc:

- There is a new addition to the clinical pathway regarding management of prolonged QTc if discovered on routine ECG (page 4 of clinical pathway)




Prolonged QTc Algorithm:

- This algorithm outlines the work up for prolonged QTc etiology
- Common QTc prolonging agents used for cancer treatment are listed at the bottom of the page
- There is also a link to an internet resource to look up medications for QTc prolonging side effect, [CredibleMeds.org](https://www.crediblemeds.org)



Prolonged QTc Algorithm:

- This algorithm also outlines the management of prolonged QTc stratified by severity



RETURN TO
THE BEGINNING




Page 1: Primary Prevention

Cancer therapy completion/End of Treatment (EOT) = from the time the patient completes their cancer therapy up until 2 years post completion

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Primary Prevention Strategies

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



Page 1: Primary Prevention


- A change in systolic performance, also known as **CTRCD**, is defined as the following:
 - EF < 55%
 - A decrease in EF of 10 percentage points or more
 - GLS < -17% (more negative is good, less negative is bad)
 - Z-scores are located in the table within an echo report. Outliers are marked in **red**
 - A decrease in EF of more than 10 percentage points from baseline
 - Example patient had a EF of 66% at one point. Then had a repeat echo which showed an EF of 56%.
 - Global longitudinal strain (GLS) is not always reported. If it is, it will be noted at the top part of the echo report under **Interpretation Summary**.

Interpretation Summary

- 1) Normal left ventricular size, well preserved global left ventricular systolic function estimated ejection fraction 58% by area length, 65.2% by 3D, shortening fraction 34%
- 2) Normal myocardial deformation parameters, GLS -19.9%, GCS -33.1%
- 3) Normal diastolic function, medial peak E velocity of 12.2 cm/s, lateral peak E velocity 18.2 cm/s
- 4) Thickness dimension ratio: 0.24
- 5) Normal end systolic wall stress estimated at 39.5 g/cm².

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Primary Prevention Strategies

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.




Page 3: Arsenic Trioxide Protocol

- Page 3 of the clinical pathway
- Patients diagnosed with APML require arsenic trioxide for their cancer treatment and should be followed accordingly
- For additional guidance from cardiology, please order a cardiology consult in Epic 
- *At this time the cardio-oncology department does not have an inpatient component.*

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Arsenic Trioxide Protocol

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



RETURN TO
THE BEGINNING



CONTACTS: OLGA H TORO SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRC
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD

LAST UPDATED: 07.17.26

©2019 Connecticut Children's Medical Center. All rights reserved.

How to place an ambulatory referral to Cardio-Oncology

A screenshot of a web-based form titled "Ambulatory referral to Cardiology". The form has a blue header bar with the title and "Accept" and "Cancel" buttons. The form fields include: "Class:" with a dropdown set to "Internal Ref"; "Referral:" with a "To dept:" dropdown showing "CARD HTFD" and a row of buttons for "CARD DANB", "CARD DKH", "CARD FARM", "CARD GLAS", "CARD HTFD", "CARD SHEL", "CARD WESTPORT", and "CARDIO ONC" (which is highlighted with a yellow box and a purple border); "To dept spec:" with a dropdown set to "Cardiology"; "To provider:" with a search and location icon; "Reason:" with a dropdown set to "Specialty Services" and buttons for "Specialty Services Required", "Second Opinion", and "Patient/Parent Preference"; "Priority:" with a dropdown set to "Routine" and buttons for "Routine", "Urgent", and "Elective"; "Type:" with a dropdown set to "Consultation"; "Reason for Consult?" with a text area; "Is this an adult congenital patient?" with "Yes" and "No" radio buttons; "Comments:" with a rich text editor; "Referral:" with "Location/POS:" and "From:" dropdowns; "To:" with a dropdown; "# of Visits:" with a text box set to "1"; and "Expiration Date:" with a date picker. At the bottom, there is a "Show Additional Order Details" link and a "Next Required" button. The form also has "Accept" and "Cancel" buttons at the bottom right.


Please make sure to select the Cardio Onc radio button under the department section, so the correct cardiologist receives the consult.

Appendix C: Echocardiogram Algorithm

- Page 1 of pathway indicates at which times to perform echocardiogram and links to this appendix
- Recalculate risk score stratification at time of every echocardiogram evaluation, which will include the trends of systolic performance (also referred to as CTRCD)

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix C: Echocardiogram Algorithm

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



RETURN TO
THE BEGINNING



CONTACTS: OLGA H TORO SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRC
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD

LAST UPDATED: 07.17.25


©2019 Connecticut Children's Medical Center. All rights reserved.

Appendix D: Cardiac MRI (CMR) Algorithm

- CMR indicated in certain clinical scenarios that are outlined on page 1 of the clinical pathway
- For patients for whom CMR is indicated, appendix D outlines our CMR protocol, including how to obtain and when to repeat imaging

Note: At this time CMRs are only scheduled on Wednesdays and Fridays

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Primary Prevention Strategies



THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT

Appendix E: Dexrazoxane Dosing

Appendix E: Dexrazoxane Administration

Dexrazoxane used only with bolus dosing of anthracycline (NOT continuous infusion)

Dosing:

- Dexrazoxane dose is 5 times the DAUNOrubicin dose
- Dexrazoxane dose is 10 times the DOXOrubicin
- Dexrazoxane dose is 6.7 times the epiRUBicin dose
- Dexrazoxane dose is 50 times the IDArubicin dose
- Dexrazoxane dose is 40 times the mitoXANtrone dose

Administration:

- Administer immediately prior to anthracycline (AC)
 - Must be within 30 minutes of beginning the AC infusion
- Administer IV over 15 minutes

CHEMOTHERAPY

Sec #	Therapeutic Exposure	Potential Late Effects
34	Anthracycline Antibiotics Daunorubicin Doxorubicin Epirubicin Idarubicin Mitoxantrone Dose Conversion Use the following formulas to convert to doxorubicin isotoxic equivalents prior to calculating total cumulative anthracycline dose.	Cardiac toxicity Cardiomyopathy Subclinical left ventricular

- Dexrazoxane dose is a 10:1 ratio per the doxorubicin isotoxic equivalents
- mitoXANtrone dose is the exception to this rule (see Appendix E)*


To estimate cumulative anthracycline dose in doxorubicin isotoxic equivalents

$1.0 \times (\text{doxorubicin total dose}) +$
 $0.5 \times (\text{daunorubicin total dose}) +$
 $0.67 \times (\text{epirubicin total dose}) +$
 $5.0 \times (\text{idarubicin total dose}) +$
 $10.0 \times (\text{mitoxantrone total dose})$

- Dexrazoxane is a cardioprotectant drug that Connecticut Children's administers prior to every bolus **anthracycline dose**. *This is not standard process world-wide*
- Per the current COG Long-Term Follow-Up Guidelines version 6, the Doxorubicin conversions are indicated here.

Page 2: Secondary Prevention Strategies

- For patients that have a change in systolic performance pathway users will be directed to page 2 of the clinical pathway



RETURN TO
THE BEGINNING



Page 2: Secondary Prevention Strategies

- Some patients with CTRCD will qualify for heart failure treatment with an ACE inhibitor to restore their heart function
- *Patients with abnormal renal function cannot receive an ACE inhibitor. Please check renal function PRIOR to starting this medication.*
- Once ACE inhibitor dose is maximized add carvedilol (on next slide, we'll review carvedilol administration appendix)
- CMR is recommended for patients on this page of the pathway

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Secondary Prevention Strategies

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Inclusion Criteria: Any pediatric cancer patient who develops change in systolic performance¹ during or after termination of cardiotoxic therapy
Exclusion criteria: No change in systolic performance during or after termination of cardiotoxic therapy

¹Definition of Change in Systolic Performance:
Left Ventricular Ejection Fraction (LVEF) AND/OR Global Longitudinal Strain (GLS) less than normal for age AND/OR Z score less than -2 OR a decrease in EF of more than 10 percentage points

Assessment:

- Obtain labs (Cardiology to obtain): High sensitivity troponin T (hsTnT), N-terminal pro-BNP (NT-proBNP), lipid panel, fructosamine, HbA1C, ferritin

Assessment:

- Obtain labs (Cardiology to obtain): High sensitivity troponin T (hsTnT), N-terminal pro-BNP (NT-proBNP), lipid panel, fructosamine, HbA1C, ferritin, vitamin D 25-hydroxy, chem 7, CBC
- Obtain follow up cardiac MRI if patient stable for procedure ([Appendix D: Cardiac MRI Algorithm](#))

- Once ACE inhibitor dose is maximized, add Carvedilol ([Appendix F: Carvedilol Administration](#))
- Consider and angiotensin receptor blocker (losartan) as an alternative to an ACE inhibitor when appropriate

Treatment

If ACE inhibitors are contraindicated, consider carvedilol as first line agent

- **Enalapril or Lisinopril (ACE inhibitors)**
 - 0-5 years of age: Enalapril 0.1 mg/kg/day PO divided twice daily; titrate upward gradually over a week to a max of 0.3mg/kg/day
 - >5 years: Enalapril 2.5 mg PO twice daily; titrate gradually over a week to a max dose of 5 mg PO twice daily
 - ≥ 12 years: Lisinopril 2.5mg PO once daily; titrate gradually over 1-2 week to a max dose of 10 mg PO once daily as tolerated
- Once ACE inhibitor dose is maximized, add Carvedilol ([Appendix F: Carvedilol Administration](#))
- Consider and angiotensin receptor blocker (losartan) as an alternative to an ACE inhibitor when appropriate
- Continue with primary prevention strategies ([page 1](#))



RETURN TO
THE BEGINNING



CONTACTS: OLGA H TORO SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRC
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
LAST UPDATED: 07.17.24

©2019 Connecticut Children's Medical Center. All rights reserved.

Appendix F: Carvedilol Administration

Background for the use of carvedilol

Dosing assistance

*Note: Carvedilol **can** be administered on days when Doxorubicin is administered*

Initiation and titration monitoring
.carvedilol SmartPhrase is available for all to utilize

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix F: Carvedilol Administration

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Appendix F: Carvedilol Administration

Dosing for Secondary and Tertiary Prevention

- Evidence for Use:
 - Beta-blockers are used extensively to treat Heart Failure (HF) because of their ability to block the neurohormonal cascade that progresses to heart disease.
 - A 2015 study of 30 mice found that LVEF was significantly lower in those receiving doxorubicin without carvedilol than in those receiving doxorubicin with carvedilol¹.
 - Considerations for patients in active therapy:
 - Carvedilol administration for primary prevention of cardiotoxicity is not yet established as standard of care.
 - There is a known Risk X category warning (PGP interaction) for simultaneous use of carvedilol and doxorubicin which may increase the concentration of doxorubicin and may increase associated adverse effects. However, after thorough investigation, it is deemed appropriate to continue carvedilol while receiving doxorubicin for secondary and tertiary prevention of cardiotoxic effects.
- Titration of Dosing*:
 - Age < 6 years old:
 - Initial: 0.05 mg/kg/dose (max 3.125 mg/dose) twice a day (BID)
 - Titrate up in 4 weeks to 0.1 mg/kg/dose
 - Titrate up in 4 weeks to 0.2 mg/kg/dose
 - Titrate up in 4 weeks to 0.35 mg/kg/dose (max 6.25 mg/dose)
 - Age ≥ 6 years old:
 - Initial: 3.125 mg BID
 - Then titrate as follows every 4 weeks :
 1. 3.125 mg BID
 2. 6.25 mg BID (Max dose <12 years of age)
 3. 9.375 mg BID
 4. 12.5 mg BID
 5. 18.75 mg BID
 6. 25 mg BID (Max dose over 18 years)

*If systolic performance is back to baseline no need to further titrate carvedilol.

- Assessment recommendations for the outpatient setting
 - Initiation/dose titration of carvedilol to be conducted in the outpatient setting.
 - For titration, patients will be instructed to take their daily carvedilol dose the evening prior to their clinic visit, and to refrain from taking the medication the morning of their visit.
 - Monitoring recommendations: Baseline blood pressure and heart rate pre-dose, and then obtain at 30-minute intervals x 3 after dose administered (30 min, 60 min, and 90 min).



RETURN TO
THE BEGINNING



CONTACTS: OLGA H TORO SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRC
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD
LAST UPDATED: 07/17/26

©2019 Connecticut Children's Medical Center. All rights reserved.


Appendix H: Endocrinology Lab Algorithm

- As part of primary prevention, endocrine labs are obtained throughout treatment as indicated on page 1
- The algorithm on appendix H outlines the actions that need to take place based upon these lab results

Green = Endocrinology labs within normal range
Yellow = Endocrinology labs slightly elevated → suggested diet modification and monitoring
Red = Endocrinology labs very elevated → refer to endocrinology

CLINICAL PATHWAY: Pediatric Cardio-Oncology Acute Cardiotoxicity Primary and Secondary Prevention Strategies Appendix H: Endocrinology Lab Algorithm

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.




CONTACTS: OLGA H TORO SALAZAR, MD, EMBA | TIFFANY BERTHOD MSN, RN, CPN, CCRC
ANDREA ORSEY, MD, MSCE | ILANA WAYNIK, MD | RAYMOND LORENZONI, MD

©2019 Connecticut Children's Medical Center. All rights reserved.

Use of Order Panel

- This **order panel** is intended for ordering the cardio-oncology labs
- Available in Epic and can be accessed by Cardiology and Cardio-Oncology *only* in ambulatory settings



The screenshot displays the 'Procedures' panel in the Epic EMR system. It features a table with five rows of procedures, each with a home icon in the first column. The columns are labeled: Name, Frequency, Type, Px Code, and Pref List. The first row is highlighted in purple. Below the table, there is a large empty light blue area. At the bottom, a search bar contains the text 'cardio' with a plus icon, and a button labeled '+ ADD DX (4)'. Above the search bar, the text 'Cardiomyopathy' is visible, along with 'Date' and 'Primary Dx' labels.

	Name	Frequency	Type	Px Code	Pref List
	CARDIO ONC LAB PANEL		Proc Panel	O2105623600	CCAMB CARD LABS
	Simple Cardio Stress Test		PFT	PFT47	CCAMB CARD STRESS TESTS
	Ambulatory Referral to Cardiology-External		Referral	REF12	CCAMB CARD REFERRALS
	Ambulatory referral to Cardiovascular Surgery (aka CARDIOLOGY)		Referral	REF14	CCAMB CARD REFERRALS
	PT Multidisciplinary Clinic - PT Eval and Treat (Cardio Onc)		PT	PT60	CCAMB CARD REFERRALS


Cardiomyopathy

cardio +  + ADD DX (4)

Date Primary Dx

Use of Smart Set

- This **SmartSet** is intended for cardiology provider use when managing a patient during an office visit
- This can be accessed by Cardiology and Cardio-Oncology by selecting the **SmartSet** or searching for it
- **SmartSet** includes templates for provider notes, orders, visit diagnoses, NYHA symptoms, commonly prescribed medications, etc.



The screenshot shows the 'SmartSets' interface. At the top, there is a search bar labeled 'Search for new SmartSet' and a '+ Add' button. A red box highlights this search area, and a red arrow points from the text 'Where you search' to it. Below the search bar, there is a section titled 'Suggestions' with a list of SmartSets, each with a checkbox. The 'Cardio Onc' SmartSet is checked. Below the suggestions, there is a section titled 'Favorites'.

SmartSet	Selected
Adult Fontan	☐
Ambulatory Suspected COVID-19	☐
CAR Electrocardiogram	☐
CAR Generic Visit	☐
Cardio Onc	☒
Cardiology Cardiac Catheterization Post-procedure	☐
Cardiology Cardiac Catheterization Pre-op	☐
Cardiology Dobutamine Stress Echo Post-procedure	☐

Where you search

- Percentage of eligible patients managed appropriately per pathway
- Percentage of patients that have labs ordered as indicated per pathway
 - If abnormal endocrine labs, percentage of patients with endocrine referral
- Percentage of patients that have physical therapy assessments performed
- Percentage of patients that have nutrition assessments performed
- Percentage of patients that have psychosocial assessment performed
- Percentage of patients with new cancer diagnosis that receive transitional education
- Percentage of patients that have risk scores performed as indicated per pathway
- Percentage of patients that have CTRCD identified via echo or CMR within a week of time indicated per pathway
 - If abnormal heart function:
 - Percentage of patients with CTRCD initiated on heart failure treatment
 - Average time to initiation of heart failure treatment

Pathway Contacts



- Ray Lorenzoni, MD
 - Cardiology
- Tiffany Berthod, MSN, RN, CPN, CCRC
 - Cardio-Oncology
- Andrea Orsey, MD, MSCE
 - Hematology/Oncology
- Ilana Waynik, MD
 - Pediatric Hospital Medicine
 - Clinical Effectiveness
- Olga Salazar, MD, MBA
 - Cardiology at Vanderbilt University Medical Center

Cardio-oncology team members we'd like to recognize that assisted with the pathway!

- Lauren Ayr-Volta, Hematology/Oncology
- Cem Demirci, Endocrinology
- Karina Engelke, Hematology/Oncology
- Michael Isakoff, Hematology/Oncology
- Mary Keller, Hematology/Oncology
- Raymond Lorenzoni, Cardiology
- Andrea Orsey, Hematology/Oncology
- Victoria Pohl, Hematology/Oncology
- Karen Rubin, Chief Clinical Transformation Officer
- Tiffany Berthod, Cardio-Oncology
- Olga Salazar, Cardiology
- Sunitha Sura, Endocrinology
- Shailendra Upadhyay, Cardiology
- Irfan Warsy, Cardiology
- Ilana Waynik, Director Clinical Effectiveness



We couldn't have done this without you all!

References



- Armenian, S. H., Gelehrter, S. K., & Chow, E. J. (2012). Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer. *Cardiol Res Pract*, 2012, 713294. <https://doi.org/10.1155/2012/713294>
- Armstrong, G. T., Liu, Q., Yasui, Y., Neglia, J. P., Leisenring, W., Robison, L. L., & Mertens, A. C. (2009). Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 27(14), 2328–2338.
- Beavers, C. J., Rodgers, J. E., Bagnola, A. J., Beckie, T. M., Campia, U., Di Palo, K. E., Okwuosa, T. M., Przespolewski, E. R., & Dent, S. (2022). Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. *Circulation*, 145(15), e811-e838. <https://doi.org/10.1161/cir.0000000000001056>
- Beck, T. C., Arhontoulis, D. C., Morningstar, J. E., Hyams, N., Stoddard, A., Springs, K., Mukherjee, R., Helke, K., Guo, L., Moore, K., Gensemer, C., Biggs, R., Petrucci, T., Kwon, J., Stayer, K., Koren, N., Harvey, A., Holman, H., Dunne, J., . . . Norris, R. A. (2022). Cellular and Molecular Mechanisms of MEK1 Inhibitor-Induced Cardiotoxicity. *JACC CardioOncol*, 4(4), 535-548. <https://doi.org/10.1016/j.jacc.2022.07.009>
- Blair, S. N., Kohl, H. W., 3rd, Paffenbarger, R. S., Jr., Clark, D. G., Cooper, K. H., & Gibbons, L. W. (1989). Physical fitness and all-cause mortality. A prospective study of healthy men and women. *Jama*, 262(17), 2395-2401. <https://doi.org/10.1001/jama.262.17.2395>
- Bosch, X., Rovira, M., Sitges, M., Domènech, A., Ortiz-Pérez, J. T., de Caralt, T. M., Morales-Ruiz, M., Perea, R. J., Monzó, M., & Esteve, J. (2013). Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). *J Am Coll Cardiol*, 61(23), 2355-2362. <https://doi.org/10.1016/j.jacc.2013.02.072>
- Bottinor, W., Im, C., Doody, D. R., Armenian, S. H., Arynchyn, A., Hong, B., Howell, R. M., Jacobs, D. R., Jr, Ness, K. K., Oeffinger, K. C., Reiner, A. P., Armstrong, G. T., Yasui, Y., & Chow, E. J. (2024). Mortality After Major Cardiovascular Events in Survivors of Childhood Cancer. *Journal of the American College of Cardiology*, 83(8), 827–838. <https://doi.org/10.1016/j.jacc.2023.12.022>
- Butel-Simoes, L. E., Haw, T. J., Williams, T., Sritharan, S., Gadre, P., Herrmann, S. M., Herrmann, J., Ngo, D. T. M., & Sverdllov, A. L. (2023). Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation. *Hypertension*, 80(4), 685-710. <https://doi.org/10.1161/hypertensionaha.122.17947>
- Campbell, K. L., Winters-Stone, K. M., Wiskemann, J., May, A. M., Schwartz, A. L., Courneya, K. S., Zucker, D. S., Matthews, C. E., Ligibel, J. A., Gerber, L. H., Morris, G. S., Patel, A. V., Hue, T. F., Perna, F. M., & Schmitz, K. H. (2019). Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. *Med Sci Sports Exerc*, 51(11), 2375-2390. <https://doi.org/10.1249/mss.0000000000002116>
- Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010). Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. *J Am Coll Cardiol*, 55(3), 213-220. <https://doi.org/10.1016/j.jacc.2009.03.095>
- Chaput, J. P., Willumsen, J., Bull, F., Chou, R., Ekelund, U., Firth, J., Jago, R., Ortega, F. B., & Katzmarzyk, P. T. (2020). 2020 WHO guidelines on physical activity and sedentary behaviour for children and adolescents aged 5-17 years: summary of the evidence. *Int J Behav Nutr Phys Act*, 17(1), 141. <https://doi.org/10.1186/s12966-020-01037-z>
- Chen, Y. L., Chung, S. Y., Chai, H. T., Chen, C. H., Liu, C. F., Chen, Y. L., Huang, T. H., Zhen, Y. Y., Sung, P. H., Sun, C. K., Chua, S., Lu, H. I., Lee, F. Y., Sheu, J. J., & Yip, H. K. (2015). Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. *J Pharmacol Exp Ther*, 355(3), 516-527. <https://doi.org/10.1124/jpet.115.225375>
- Cheung, A. T., Li, W. H. C., Ho, L. L. K., Ho, K. Y., Chan, G. C. F., & Chung, J. O. K. (2021). Physical activity for pediatric cancer survivors: a systematic review of randomized controlled trials. *J Cancer Surviv*, 15(6), 876-889. <https://doi.org/10.1007/s11764-020-00981-w>
- Chovanec, J., Chovanec, M., & Mego, M. (2020). Levels of NT-proBNP and Troponin T in Cancer Patients - Mini-Review. *Klin Onkol*, 33(3), 171-176. <https://doi.org/10.14735/amko2020171> (Hladiny NT-proBNP a troponínu T u onkologických pacientov - stručný prehľad.)
- de Baat, E. C., Feijen, E. A. M., Reulen, R. C., Allodji, R. S., Bagnasco, F., Bardi, E., Belle, F. N., Byrne, J., van Dalen, E. C., Debiche, G., Diallo, I., Grabow, D., Hjorth, L., Jankovic, M., Kuehni, C. E., Levitt, G., Llanas, D., Loonen, J., Zaletel, L. Z., . . . Kremer, L. C. M. (2023). Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study. *J Clin Oncol*, 41(1), 96-106. <https://doi.org/10.1200/jco.21.02944>

References



- de Ferranti, S. D., Steinberger, J., Ameduri, R., Baker, A., Gooding, H., Kelly, A. S., Mietus-Snyder, M., Mitsnefes, M. M., Peterson, A. L., St-Pierre, J., Urbina, E. M., Zachariah, J. P., & Zaidi, A. N. (2019). Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. *Circulation*, 139(13), e603-e634. <https://doi.org/10.1161/cir.0000000000000618>
- Dillon, H. T., Foulkes, S. J., Baik, A. H., Scott, J. M., Touyz, R. M., Herrmann, J., Haykowsky, M. J., La Gerche, A., & Howden, E. J. (2024). Cancer Therapy and Exercise Intolerance: The Heart Is But a Part: JACC: CardioOncology State-of-the-Art Review. *JACC. CardioOncology*, 6(4), 496–513. <https://doi.org/10.1016/j.jaccao.2024.04.006>
- Fernandes, T., Baraúna, V. G., Negrão, C. E., Phillips, M. I., & Oliveira, E. M. (2015). Aerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAs. *Am J Physiol Heart Circ Physiol*, 309(4), H543-552. <https://doi.org/10.1152/ajpheart.00899.2014>
- Foulkes, S. J., Howden, E. J., Haykowsky, M. J., Antill, Y., Salim, A., Nightingale, S. S., Loi, S., Claus, P., Janssens, K., Mitchell, A. M., Wright, L., Costello, B. T., Lindqvist, A., Burnham, L., Wallace, I., Daly, R. M., Fraser, S. F., & La Gerche, A. (2023). Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study. *Circulation*, 147(7), 532-545. <https://doi.org/10.1161/circulationaha.122.062814>
- Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J., Jones, R. J., Petrie, M. C., & Lang, N. N. (2022). Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review. *JACC CardioOncol*, 4(1), 1-18. <https://doi.org/10.1016/j.jaccao.2022.01.096>
- Groarke, J. D., Nguyen, P. L., Nohria, A., Ferrari, R., Cheng, S., & Moslehi, J. (2014). Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. *Eur Heart J*, 35(10), 612-623. <https://doi.org/10.1093/eurheartj/ehz114>
- Groarke, J. D., Payne, D. L., Claggett, B., Mehra, M. R., Gong, J., Caron, J., Mahmood, S. S., Hainer, J., Neilan, T. G., Partridge, A. H., Di Carli, M., Jones, L. W., & Nohria, A. (2020). Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. *Eur Heart J Qual Care Clin Outcomes*, 6(4), 315-322. <https://doi.org/10.1093/ehjqcco/qcaa015>
- Gupta, V., Kumar Singh, S., Agrawal, V., & Bali Singh, T. (2018). Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial. *Pediatr Blood Cancer*, 65(11), e27308. <https://doi.org/10.1002/pbc.27308>
- Hamer, M., Ingle, L., Carroll, S., & Stamatakis, E. (2012). Physical activity and cardiovascular mortality risk: possible protective mechanisms? *Med Sci Sports Exerc*, 44(1), 84-88. <https://doi.org/10.1249/MSS.0b013e3182251077>
- Hammoud, R. A., Mulrooney, D. A., Rhea, I. B., Yu, C., Johnson, J. N., Chow, E. J., Ehrhardt, M. J., Hudson, M. M., Ness, K. K., Armstrong, G. T., & Dixon, S. B. (2024). Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer: JACC: CardioOncology State-of-the-Art Review. *JACC. CardioOncology*, 6(1), 16–32. <https://doi.org/10.1016/j.jaccao.2023.12.008>
- Harries, I., Liang, K., Williams, M., Berlot, B., Biglino, G., Lancellotti, P., Plana, J. C., & Bucciarelli-Ducci, C. (2020). Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review. *JACC CardioOncol*, 2(2), 270-292. <https://doi.org/10.1016/j.jaccao.2020.04.011>
- Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., Milano, C. A., ... ACC/AHA Joint Committee Members (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, 145(18), e895–e1032. <https://doi.org/10.1161/CIR.0000000000001063>
- Herrmann, J. (2020). Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. *Nat Rev Cardiol*, 17(8), 474-502. <https://doi.org/10.1038/s41569-020-0348-1>
- Hoffmann, T. C., Maher, C. G., Briffa, T., Sherrington, C., Bennell, K., Alison, J., Singh, M. F., & Glasziou, P. P. (2016). Prescribing exercise interventions for patients with chronic conditions. *Cmaj*, 188(7), 510-518. <https://doi.org/10.1503/cmaj.150684>
- Jeong, S. W., Kim, S. H., Kang, S. H., Kim, H. J., Yoon, C. H., Youn, T. J., & Chae, I. H. (2019). Mortality reduction with physical activity in patients with and without cardiovascular disease. *Eur Heart J*, 40(43), 3547-3555. <https://doi.org/10.1093/eurheartj/ehz564>
- Joshi, A. M., Prousi, G. S., Bianco, C., Malla, M., Guha, A., Shah, M., Brown, S. A., & Patel, B. (2021). Microtubule Inhibitors and Cardiotoxicity. *Current oncology reports*, 23(3), 30. <https://doi.org/10.1007/s11912-021-01014-0>

References



- Kavanagh, T., Mertens, D. J., Hamm, L. F., Beyene, J., Kennedy, J., Corey, P., & Shephard, R. J. (2003). Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. *J Am Coll Cardiol*, 42(12), 2139-2143. <https://doi.org/10.1016/j.jacc.2003.07.028>
- Kodama, S., Saito, K., Tanaka, S., Maki, M., Yachi, Y., Asumi, M., Sugawara, A., Totsuka, K., Shimano, H., Ohashi, Y., Yamada, N., & Sone, H. (2009). Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *Jama*, 301(19), 2024-2035. <https://doi.org/10.1001/jama.2009.681>
- Korosoglou, G., Giusca, S., Montenbruck, M., Patel, A. R., Lapinskas, T., Götze, C., Zieschang, V., Al-Tabatabaee, S., Pieske, B., Florian, A., Erley, J., Katus, H. A., Kelle, S., & Steen, H. (2021). Fast Strain-Encoded Cardiac Magnetic Resonance for Diagnostic Classification and Risk Stratification of Heart Failure Patients. *JACC Cardiovasc Imaging*, 14(6), 1177-1188. <https://doi.org/10.1016/j.jcmg.2020.10.024>
- Lipshultz, S. E., Franco, V. I., Miller, T. L., Colan, S. D., & Sallan, S. E. (2015). Cardiovascular disease in adult survivors of childhood cancer. *Annual review of medicine*, 66, 161-176. <https://doi.org/10.1146/annurev-med-070213-054849>
- Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., & Sallan, S. E. (2004). The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. *N Engl J Med*, 351(2), 145-153. <https://doi.org/10.1056/NEJMoa035153>
- Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., . . . van der Pal, H. J. H. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J*, 43(41), 4229-4361. <https://doi.org/10.1093/eurheartj/ehac244>
- Mertens, L., Singh, G., Armenian, S., Chen, M. H., Dorfman, A. L., Garg, R., Husain, N., Joshi, V., Leger, K. J., Lipshultz, S. E., Lopez-Mattei, J., Narayan, H. K., Parthiban, A., Pignatelli, R. H., Toro-Salazar, O., Wasserman, M., & Wheatley, J. (2023). Multimodality Imaging for Cardiac Surveillance of Cancer Treatment in Children: Recommendations From the American Society of Echocardiography. *Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography*, 36(12), 1227-1253. <https://doi.org/10.1016/j.echo.2023.09.009>
- Patel, A. V., Friedenreich, C. M., Moore, S. C., Hayes, S. C., Silver, J. K., Campbell, K. L., Winters-Stone, K., Gerber, L. H., George, S. M., Fulton, J. E., Denlinger, C., Morris, G. S., Hue, T., Schmitz, K. H., & Matthews, C. E. (2019). American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control. *Med Sci Sports Exerc*, 51(11), 2391-2402. <https://doi.org/10.1249/mss.0000000000002117>
- Piña, I. L., Apstein, C. S., Balady, G. J., Belardinelli, R., Chaitman, B. R., Duscha, B. D., Fletcher, B. J., Fleg, J. L., Myers, J. N., & Sullivan, M. J. (2003). Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. *Circulation*, 107(8), 1210-1225. <https://doi.org/10.1161/01.cir.0000055013.92097.40>
- Plana, J. C., Thavendiranathan, P., Bucciarelli-Ducci, C., & Lancellotti, P. (2018). Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient. *JACC Cardiovasc Imaging*, 11(8), 1173-1186. <https://doi.org/10.1016/j.jcmg.2018.06.003>
- Ross, R., Blair, S. N., Arena, R., Church, T. S., Després, J. P., Franklin, B. A., Haskell, W. L., Kaminsky, L. A., Levine, B. D., Lavie, C. J., Myers, J., Niebauer, J., Sallis, R., Sawada, S. S., Sui, X., & Wisløff, U. (2016). Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. *Circulation*, 134(24), e653-e699. <https://doi.org/10.1161/cir.0000000000000461>
- Ryan, T. D., Bates, J. E., Kinahan, K. E., Leger, K. J., Mulrooney, D. A., Narayan, H. K., Ness, K., Okwuosa, T. M., Rainusso, N. C., Steinberger, J., Armenian, S. H., & Pediatric Heart Failure & Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology (2025). Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association. *Circulation*, 10.1161/CIR.0000000000001308. Advance online publication. <https://doi.org/10.1161/CIR.0000000000001308>
- Scott, J. M., Lakoski, S., Mackey, J. R., Douglas, P. S., Haykowsky, M. J., & Jones, L. W. (2013). The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics. *Oncologist*, 18(2), 221-231. <https://doi.org/10.1634/theoncologist.2012-0226>

References



- Selvin, E., Rawlings, A. M., Grams, M., Klein, R., Sharrett, A. R., Steffes, M., & Coresh, J. (2014). Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. *Lancet Diabetes Endocrinol*, 2(4), 279-288. [https://doi.org/10.1016/s2213-8587\(13\)70199-2](https://doi.org/10.1016/s2213-8587(13)70199-2)
- Sepe, D. M., Ginsberg, J. P., & Balis, F. M. (2010). Dexrazoxane as a cardioprotectant in children receiving anthracyclines. *Oncologist*, 15(11), 1220-1226. <https://doi.org/10.1634/theoncologist.2010-0162>
- Testi, A. M., Pession, A., Diverio, D., Grimwade, D., Gibson, B., de Azevedo, A. C., Moran, L., Leverger, G., Elitzur, S., Hasle, H., van der Werff ten Bosch, J., Smith, O., De Rosa, M., Piciocchi, A., Lo Coco, F., Foà, R., Locatelli, F., & Kaspers, G. J. L. (2018). Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. *Blood*, 132(4), 405-412. <https://doi.org/10.1182/blood-2018-03-836528>
- Tonorezos, E. S., Snell, P. G., Moskowitz, C. S., Eshelman-Kent, D. A., Liu, J. E., Chou, J. F., Smith, S. M., Dunn, A. L., Church, T. S., & Oeffinger, K. C. (2013). Reduced cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer*, 60(8), 1358-1364. <https://doi.org/10.1002/pbc.24492>
- Toro-Salazar, O. H., Ferranti, J., Lorenzoni, R., Walling, S., Mazur, W., Raman, S. V., Davey, B. T., Gillan, E., O'Loughlin, M., Klas, B., & Hor, K. N. (2016). Feasibility of Echocardiographic Techniques to Detect Subclinical Cancer Therapeutics-Related Cardiac Dysfunction among High-Dose Patients When Compared with Cardiac Magnetic Resonance Imaging. *J Am Soc Echocardiogr*, 29(2), 119-131. <https://doi.org/10.1016/j.echo.2015.10.008>
- Toro-Salazar, O. H., Gillan, E., Ferranti, J., Orsey, A., Rubin, K., Upadhyay, S., Mazur, W., & Hor, K. N. (2015). Effect of myocardial dysfunction in cardiac morbidity and all cause mortality in childhood cancer subjects treated with anthracycline therapy. *Cardiooncology*, 1(1), 1. <https://doi.org/10.1186/s40959-015-0005-8>
- Tukenova, M., Guibout, C., Oberlin, O., Doyon, F., Mousannif, A., Haddy, N., Guérin, S., Pacquement, H., Aouba, A., Hawkins, M., Winter, D., Bourhis, J., Lefkopoulos, D., Diallo, I., & de Vathaire, F. (2010). Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. *J Clin Oncol*, 28(8), 1308-1315. <https://doi.org/10.1200/jco.2008.20.2267>
- Unnikrishnan, D., Dutcher, J. P., Varshneya, N., Lucariello, R., Api, M., Garl, S., Wiernik, P. H., & Chiaramida, S. (2001). Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. *Blood*, 97(5), 1514-1516. <https://doi.org/10.1182/blood.v97.5.1514>
- van der Schoot, G. G. F., Ormel, H. L., Westerink, N. L., May, A. M., Elias, S. G., Hummel, Y. M., Lefrandt, J. D., van der Meer, P., van Melle, J. P., Poppema, B. J., Stel, J. M. A., van der Velden, A. W. G., Vrieling, A. H., Wempe, J. B., Ten Wolde, M. G., Nijland, M., de Vries, E. G. E., Gietema, J. A., & Walenkamp, A. M. E. (2022). Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy. *JACC CardioOncol*, 4(4), 491-503. <https://doi.org/10.1016/j.jaccao.2022.07.006>
- Wanderley, M. R. B., Jr., Ávila, M. S., Fernandes-Silva, M. M., Cruz, F. D. D., Brandão, S. M. G., Rigaud, V. O. C., Hajjar, L. A., Filho, R. K., Cunha-Neto, E., Bocchi, E. A., & Ayub-Ferreira, S. M. (2022). Plasma biomarkers reflecting high oxidative stress in the prediction of myocardial injury due to anthracycline chemotherapy and the effect of carvedilol: insights from the CECY Trial. *Oncotarget*, 13, 214-223. <https://doi.org/10.18632/oncotarget.28182>
- Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019). Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring. *Mol Pharmacol*, 96(2), 219-232. <https://doi.org/10.1124/mol.119.115725>
- Wilson, R. L., Christopher, C. N., Yang, E. H., Barac, A., Adams, S. C., Scott, J. M., & Dieli-Conwright, C. M. (2023). Incorporating Exercise Training into Cardio-Oncology Care: Current Evidence and Opportunities: JACC: CardioOncology State-of-the-Art Review. *JACC. CardioOncology*, 5(5), 553-569. <https://doi.org/10.1016/j.jaccao.2023.08.008>
- Winter, C., Müller, C., Hoffmann, C., Boos, J., & Rosenbaum, D. (2010). Physical activity and childhood cancer. *Pediatr Blood Cancer*, 54(4), 501-510. <https://doi.org/10.1002/pbc.22271>
- Zukkoor Zorn, S., & Thohan, V. (2018). *Drug-Drug Interactions of Common Cardiac Medications and Chemotherapeutic Agents*. American College of Cardiology. <https://www.acc.org/latest-in-cardiology/articles/2018/12/21/09/52/drug-drug-interactions-of-common-cardiac-medications-and-chemotherapeutic-agents>

Thank You!



About Connecticut Children's Pathways Program

Clinical pathways guide the management of patients to **optimize consistent use** of evidence-based practice. Clinical pathways have been shown to improve guideline adherence and quality outcomes, while decreasing length of stay and cost. Here at Connecticut Children's, our Clinical Pathways Program **aims to deliver evidence-based, high value care to the greatest number of children in a diversity of patient settings.**

These pathways serve as a guide for providers and **do not** replace clinical judgment.